drugset
drugset / Trial / NCT05535673

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

NCT05535673 ↗

Phase 1 Unknown 15 enrolled Zhengzhou University Fundamenta Therapeutics, Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single dose escalation study to evaluate the safety, efficacy and pharmacokinetics of ThisCART19A (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell Lymphoma.

Timeline

Start
2022-09-02
Primary completion
2025-07-01
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ThisCART19A Cell therapy — —

Indications

No indication recorded.